As a first step, they have agreed on a technology transfer for the unique isotope ITG Lu-177 noncarrier added (n.c.a.). Lutetium-177 is used in nuclear medicine for the treatment of neuroendocrine tumors. NTP has in-licensed the production technology and will become the exclusive distribution partner for ITG.
In addition, ITG will expand its global reactor network by cooperating with NECSA's Safari-1 nuclear reactor. The Safari-1 nuclear reactor is one of five reactors in the world that together produce 98% of the world's radionuclides for medical use.
Copyright © 2012 AuntMinnieEurope.com